Strait Access Technologies
Julian Lea has extensive work experience in various leadership roles in the automotive industry. Julian currently serves as the Chief Operating Officer at Strait Access Technologies, a position they have held since September 2021. Prior to that, Julian was the Head of Business Affairs at the same company from April 2018 to August 2021.
Before joining Strait Access Technologies, Julian worked as a Management Consultant at GLG (Gerson Lehrman Group) from September 2015. Julian was responsible for providing strategic, process, organizational, and lean operations advice to a global client base.
Julian also held several roles at Lexus UK, including Head of Brand & Product Planning from July 2011 to December 2014, National Manager: Strategy & Planning from June 2010 to September 2011, and National Manager: Marketing from January 2009 to May 2010. In these positions, they played a key role in managing the product portfolio, setting the strategic agenda, and efficiently deploying marketing budgets.
Prior to their time at Lexus UK, Julian worked at Toyota GB as the Head of Sales and Demand/Supply Planning from April 2003 to December 2008. During this time, they successfully optimized the supply/demand balance for over 130,000 cars per year, leading to recognition as a top-performing team in Europe.
Julian's early career includes roles at BMW and General Motors, where they served as a Product & Brand Manager and Brand Strategy Manager, respectively.
Overall, Julian Lea's work experience demonstrates their strong leadership capabilities and expertise in strategic planning, operations, and brand management within the automotive industry.
Julian Lea attended Hilton College from 1983 to 1986. Julian then went on to study at the University of Cape Town from 1987 to 1990, where they obtained a Bachelor of Social Science degree, with a focus on Economics and Marketing.
This person is not in any teams
Strait Access Technologies
Rheumatic Heart Disease (RHD) is an easily preventable type of heart disease caused by streptococcal bacteria. This bacteria is responsible for a common throat infection known as strep throat. When left untreated, a patient’s immune system can turn against his own heart while fighting the infection. This can lead to an acute inflammation of the heart accompanied by high fever (acute rheumatic fever). The inflammation can damage heart valves irreversibly. The disease mainly affects children between the ages 5 -15, and occurs approximately 14–28 days after symptoms of strep throat or scarlet fever appear. According to conservative and outdated WHO estimates, 15 million people are affected by the disease globally. Newer statistics argue that the number could be up to five times higher, at 60–75 million people worldwide. Rheumatic Heart Disease is much more prevalent among those living in developing countries, especially sub–Saharan Africa, due to limited access to quality healthcare and antibiotics. Rheumatic Heart Disease claims the lives of 1.4 million people per annum, with up to 70% of patients will dying before the age of 26. Although Rheumatic heart disease affects mainly the poor, all current heart valve technologies are focused on developed first world applications. These devices are highly sophisticated and make use of advanced monitoring equipment that requires highly specialised operators. Overall, neither skilled surgeons or cardiologists nor monitoring or imaging equipment and hospital facilities are available in the countries where Rheumatic Heart Disease is most prevalent. Due to this, of every 100 patients requiring heart valve replacement, only two patients are treated worldwide. With SAT’s technology this could change.